Compass Pathways Projects FY2025 Net Cash Use of $120M-$145M

LOS ANGELES- Compass Pathways plc a mental health care company specializing in psilocybin therapy, has announced an expected net cash utilization of $120 million to $145 million for the fiscal year 2025. As of February 27, 2025, the company’s cash reserves are projected to support operational and capital expenditures through the anticipated 26-week data readout from the COMP006 study, scheduled for the latter half of 2026.

In its fourth-quarter 2024 financial report, Compass Pathways reported an earnings per share (EPS) loss of $0.63, slightly below the consensus estimate of a $0.62 loss. CEO Kabir Nath highlighted the company’s progress, stating that the first data readout from the pivotal Phase 3 COMP360 program for treatment-resistant depression remains on track, with top-line six-week data expected in the upcoming quarter. Additionally, the company is advancing plans for a late-stage clinical program targeting post-traumatic stress disorder (PTSD), leveraging resources from a recent financing round in January.